Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Votan2015on Mar 25, 2020 2:23pm
69 Views
Post# 30846484

RE:Why didn’t our ceo and board look at all options

RE:Why didn’t our ceo and board look at all options
edrose wrote: To raise money several months ago to pay off talent   Is it because this would spoil their buddy bassada and company takeover of kly.  I don’t know but we all know they had other options to raise money and they used them   Few simple ones they could have used an ATM when sp was much higher and they knew long time ago they needed money they could ALSO DO RIGHTS OFFERING WITH KLY’S RETAIL INVESTORS  just these 2 things we could have raised money  
 WHY DO YOU THIS WAS NOT OFFERED AND EXERCISED MUCH LESS DILUTIVE AND WE KEEP OUR COMPANY INSTEAD OF LOSING TO BASSADA/STERO

WITH GREAT PHASE2 RESULTS ASK YOURSELF HOW HARD DID THEY LOOK IN FINDING A LICENCING DEAL FOR A PRODUCT CLOSE TO BEING APPROVED WHETE THER’S NO CURRENT TREAMENT AND CONSERVATIVE ESTIMATE 500 MILLION SALES FIRST YEAR 


They had enough time to find a proper financing, even to renegotiate payments to Talent shareholders which are the same people from our so called managment. They have neglected any possible positive solution for the shareholders. It seems the plan had been executed around one year ago meanwhile we were fed with the 3 NRs regarding buyout, licensing and partnership. We are kept in dark regarding the value of Stero, their research and financing. In my opinion they are dealing with themselves using our money.
Bullboard Posts